

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
				to malignant disease, e.g. adrenocortical carcinoma or ectopic ACTH syndrome, in place of or in conjunction with surgery.	
00101/0533	Novartis Pharmaceuticals UK Limited	Prescal Concentrate for Infusion 1mg/1ml	Isradipine HSE 1.0mg	Prescription Only Medicine Treatment of hypertension following coronary surgery.	17th November 1997
00101/0534	Novartis Pharmaceuticals UK Limited	Prescal LS 1.25mg	Isradipine HSE 1.25mg	Prescription Only Medicine For the treatment of essential hypertension.	17th November 1997
00101/0535	Novartis Pharmaceuticals UK Limited	Prescal Retard Capsules 1.25mg	Isradipine 2.500mg	Prescription Only Medicine For the treatment of essential hypertension.	17th November 1997
00101/0536	Novartis Pharmaceuticals UK Limited	Prescal Retard Capsules 5mg	Isradipine 5.000mg	Prescription Only Medicine For the treatment of essential hypertension.	17th November 1997
00101/0537	Novartis Pharmaceuticals UK Limited	Prescal Tablets 2.5mg	Isradipine HSE 2.5mg	Prescription Only Medicine See PL00101/0534	17th November 1997
00101/0538	Novartis Pharmaceuticals UK Limited	Prescal Tablets 5mg	Isradipine HSE 5.0mg	Prescription Only Medicine See PL00101/0534	17th November 1997
00101/0541	Novartis Pharmaceuticals UK Limited	Scopoderm TTS	Drug Reservoir: Scopolamine (Hyoscine) USP 1.31mg Adhesive (to skin): Scopolamine (Hyoscine) USP 0.23mg	Prescription Only Medicine For the prevention of symptoms of motion sickness such as nausea, vomiting and vertigo.	17th November 1997
00101/0542	Novartis Pharmaceuticals UK Limited	Slow-K Tablets 600mg	Potassium Chloride BP 600mg	Pharmacy Medicine For the correction and/or prevention of hypokalaemia in those patients who cannot tolerate and/or refuse to take liquid or effervescent potassium chloride, or when there is a problem of compliance with these preparations.	17th November 1997
00101/0543	Novartis Pharmaceuticals UK Limited	Synacthen Ampoules 250mcg	Tetracosactrin (as acetate) BP 0.25mg	Prescription Only Medicine As a diagnostic test for the investigation of adrenocortical insufficiency.	17th November 1997
00101/0544	Novartis Pharmaceuticals UK Limited	Synacthen Depot Ampoules 1mg/1ml	Tetracosactrin (As Acetate) BP 1mg	Prescription Only Medicine Should normally only be used for short-term therapy in conditions for which glucocorticoids are indicated in principal, for example, in ulcerative colitis and Chron's Disease, juvenile rheumatoid arthritis, or as adjunct therapy in patients with rheumatoid arthritis and osteoarthritis. Synacthen depot may be particularly useful in patients unable to tolerate oral glucocorticoid therapy or patients where normal therapeutic doses of glucocorticoids have been ineffective.	17th November 1997
00101/0545	Novartis Pharmaceuticals UK Limited	Tofranil Syrup	Tofranil Resin Compound* Imipramine Hydrochloride BP 25.00mg *Prepared from: Imipramine base (Pharma grade) 22.12mg Purolite C108 (Purified) (= 66.36mg dried weight)	Prescription Only Medicine Symptoms of depressive illness. Relief of nocturnal enuresis in children.	17th November 1997
00101/0546	Novartis Pharmaceuticals UK Limited	Tofranil Tablets 10mg	Imipramine Hydrochloride BP 10.00mg	Prescription Only Medicine Symptoms of depressive illness. Relief of nocturnal enuresis in children.	17th November 1997
00101/0547	Novartis Pharmaceuticals UK Limited	Tofranil Tablets 25mg	Imipramine Hydrochloride BP 25.00mg	Prescription Only Medicine See PL00101/0546	17th November 1997
00116/0274	Baxter Healthcare Limited	Ivelip 10%	Soybean Oil 10.000wv	Prescription Only Medicine See PL0116/0275	1st November 1997
00116/0275	Baxter Healthcare Limited	Ivelip 20%	Soybean Oil 20.000wv	Prescription Only Medicine As a source of calories and essential fatty acids for patients requiring parenteral nutrition.	1st November 1997
00116/0283	Baxter Healthcare Limited	Primene 10%	L-Isoleucine HSE 0.670g L-Leucine HSE 1.000g L-Valine HSE 0.760g L-Lysine HSE 1.100g	Prescription Only Medicine See PL00116/0284	1st November 1997